- Home
- PSF vs PRQR Comparison
PSF vs PRQR Comparison
Compare PSF & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSF
- PRQR
- Stock Information
- Founded
- PSF 2010
- PRQR 2012
- Country
- PSF United States
- PRQR Netherlands
- Employees
- PSF N/A
- PRQR N/A
- Industry
- PSF Investment Managers
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- PSF Finance
- PRQR Health Care
- Exchange
- PSF Nasdaq
- PRQR Nasdaq
- Market Cap
- PSF 245.5M
- PRQR 232.8M
- IPO Year
- PSF N/A
- PRQR 2014
- Fundamental
- Price
- PSF $20.96
- PRQR $2.06
- Analyst Decision
- PSF
- PRQR Strong Buy
- Analyst Count
- PSF 0
- PRQR 8
- Target Price
- PSF N/A
- PRQR $8.88
- AVG Volume (30 Days)
- PSF 25.0K
- PRQR 368.1K
- Earning Date
- PSF 01-01-0001
- PRQR 11-06-2025
- Dividend Yield
- PSF 7.69%
- PRQR N/A
- EPS Growth
- PSF N/A
- PRQR N/A
- EPS
- PSF N/A
- PRQR N/A
- Revenue
- PSF N/A
- PRQR $20,129,184.00
- Revenue This Year
- PSF N/A
- PRQR N/A
- Revenue Next Year
- PSF N/A
- PRQR N/A
- P/E Ratio
- PSF N/A
- PRQR N/A
- Revenue Growth
- PSF N/A
- PRQR 8.65
- 52 Week Low
- PSF $16.00
- PRQR $1.07
- 52 Week High
- PSF $20.19
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- PSF 73.93
- PRQR 42.63
- Support Level
- PSF $20.58
- PRQR $1.91
- Resistance Level
- PSF $20.60
- PRQR $2.50
- Average True Range (ATR)
- PSF 0.16
- PRQR 0.16
- MACD
- PSF 0.05
- PRQR -0.04
- Stochastic Oscillator
- PSF 82.97
- PRQR 25.42
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.